X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Elevating Vaccine Stability Through Predicting mRNA Degrades

Content Team by Content Team
13th April 2023
in IPR Data Management, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Messenger ribonucleic acid (mRNA) as a therapeutic method is gaining traction due to its ease of production and promising results.

mRNA-based vaccines, for example, have been critical in the fight against COVID-19 in many parts of the world. Yet, because of their thermal instability, mRNA-based therapies can be vulnerable to chemical destruction. As a result, mRNA vaccines require demanding manufacturing, storage, and robust international distribution. Understanding and improving the stability of mRNA vaccines is crucial for making them more widely available.

Dr. Qing Sun, a professor in Texas A&M University’s Artie McFerrin Department of Chemical Engineering, and a group of graduate students created a successful and interpretable model using deep-learning methods that can predict RNA degradation more appropriately than previous best methods such as Degscore models, RNA folding algorithms, as well as other machine-learning models. Their model was put to the test, and the results were recently reported in briefings in bioinformatics.

According to Sun, the intrinsic temperature instability of mRNA has restricted the global distribution of mRNA vaccines due to in-line hydrolysis, a chemical degradation reaction. As a result, their research aims to comprehend and anticipate mRNA breakdown. To address this issue, Sun and her colleagues turned to deep-learning approaches, creating the RNAdegformer, a deep-learning-based model supported by artificial neural networks that have the ability to gather data and apply this knowledge to create predictions.

Sun claims that the RNAdegformer analyses RNA sequences with self-attention and repetitions, two deep-learning approaches that have proven dominant in the realms of computer vision and natural language processing, while exploiting the biophysical properties of RNA secondary structure features and base pairing probabilities.

She further added that the RNAdegformer exceeds prior best approaches at predicting degradation qualities at the nucleotide level, which are like sentences’ letters that combine to produce mRNA. Each nucleotide of the COVID-19 mRNA vaccine can be predicted. When compared to prior best methods, RNAdegformer predictions have a better connection with RNA’s in vitro half-life.

Furthermore, the study demonstrates how direct visualisation of self-attention maps aids in informed decision-making. According to Shujun He, the paper’s first author and a graduate student in Sun’s group, attention maps demonstrate how the model thinks using input information, which aids in making knowledgeable decisions based on model predictions. Furthermore, their model indicates critical characteristics in determining mRNA degradation rates.

Researchers partnered with Rhiju Das, an associate professor of biochemistry at Stanford University, whose high-quality mRNA degradation data served as the study’s starting point. With this research, they aim to be able to build more stable mRNA vaccines using their methodology, allowing for more equity and a broader use of mRNA therapies, Sun added.

Previous Post

Microbial Fermentation Tech Market To Go Beyond $56b In 2023

Next Post

Customised Blood Pressure Treatment Can Get More Protection

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Customised Blood Pressure Treatment Can Get More Protection

Customised Blood Pressure Treatment Can Get More Protection

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In